ClinicalTrials.gg
Not yet recruitingNCT07640919ArrhythmiaUpdated Jun 11, 2026

Patterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease

An observational study in Chronic Kidney Disease With and Without Hemodialysis, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Sohag University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.

Planned enrollment
6th of 20
200 · median 110
Started
2026
with 8 others
Observational
20 of 64
8 open now
Primary completion
2026-12
later than 20 of 27 live
Registered
60th of 64
by date
Lead sponsor
6 of 64
Sohag University

Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 6th largest by planned enrollment of the 20 observational ones that give a count, is one of 9 that started in 2026, is one of 20 observational ones, reaches primary completion later than 20 of the 27 other live ones, and was the 60th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in Egypt, or all of them as a file.
02

Study summary

Cardiovascular diseases remain the primary leading cause of death in patients on maintenance hemodialysis accounting for nearly 41% of deaths.

Chronic kidney disease is associated with an excess of acquired arrhythmia of multiple types, and atrial fibrillation in particular.

Sudden cardiac death is also more common in chronic kidney disease and accounts for around one- quarter of deaths in dialysis patients.

The aim of the study is to evaluate the incidence, describe the patterns of cardiac arrhythmia and to determine the factors predisposing to cardiac arrhythmia in patients with chronic kidney disease with or without hemodialysis.

Read the detailed description

After obtaining written, informed consents, individuals are subjected to thorough clinical evaluation (age, sex, history of hypertension (HTN) or diabetes mellitus (DM)) and laboratory tests including complete blood count, urea, creatinine, glomerular filtration rate (eGFR) (calculated by CKD-EPI equation) , serum potassium, magnesium, calcium, phosphorus, parathyroid hormone (PTH), iron and total iron binding capacity (TIBC).

Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: heart rhythm, heart rate, frontal axis, P wave, PR interval, QRS duration, pathological Q wave, fragmented QRS morphology, ST-segment deviation, QT interval and T wave abnormality.

03

Conditions studied

  • Chronic Kidney Disease With and Without Hemodialysis

Keywords

  • chronic kidney disease (CKD)
  • cardiac arrhythmia
  • atrial fibrillation (AF)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with chronic kidney disease at hemodialysis unit and outpatient nephrology clinic at Sohag university hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with CKD (no intercurrent illness or uremic symptoms, and not hospitalized in the previous 3 months) with renal replacement therapy on maintenance HD (three times/week for at least three months) or without renal replacement therapy, aged 18 or above.

Exclusion criteria

Exclusion Criteria:

  • Patients aged \<18 years old.
  • Patients on drugs that are known to prolong the (e.g., antibiotics as clarithromycin, antifungal as fluconazole, antiarrhythmics as amiodarone, antipsychotic as chlorpromazine)
  • Patients with structural heart diseases (e.g.,significant valvular lesions )
  • Patients with impaired left ventricular systolic functions (defined as EF\< 50%
  • Patients with , severe infection or sepsis.
  • Patients with major bleeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Detection of changes (already exsited) in heart rate (measured in beats/ minutes) and corrected QT interval (measured in milliseconds) from normal limits in patients with chronic kidney disease.

    Twelve-lead ECG is performed and all ECGs are reviewed for the following parameters: * heart rate (measured by beats/minutes) normal limit: 60 - 100 b/m * corrected QT interval (measured in milliseconds) normal limit: 330 - 440 ms in males and 330 - 450 in female

    Time frame: Health survey distributed during 4 months to determine how many patients with chronic kidney disease have cardiac arrhythmia in hemodialysis unit and outpatient nephrology clinic at sohag university hospitals

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 11, 2026
StartEst.
Jul 20, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Jan 20, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640919
Lead sponsor
Sohag University
Responsible party
Magy Mogahed Mounir (Resident doctor at internal medicine department, Sohag University) — Principal investigator
First posted
Jun 11, 2026
Start date
Jul 20, 2026 (estimated)
Primary completion
Dec 20, 2026 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Magi Mogahed Mounir, Resident doctor
Contact
magi.mogahed@med.sohag.edu.eg
00201276347105
Noher Mohamad Abass, Associate professor
Contact
nohermohamed3581@gmail.com
00201224921932
Emad Ahmad Mohamad, Associate professor
study director · Faculty of medicine, Sohag university, Internal medicine department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion